-
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their new puppy brings a...
IN THE SPOTLIGHT
-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
Weekly Virtual Meetup
For patients/survivors - Join us every Tuesday at 12 pm ET for this general meetup for anyone impacted by lung cancer. After registering, you will receive a confirmation email... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects...
The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC)
The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC)
Arteannuin B Inhibits NSCLC Cells via Regulating miR‐194‐3p/CLDN2 Axis
Real-world cardiovascular risk comparison of first-line osimertinib and earlier generation EGFR-TKIs in EGFR-mutated NSCLC: a TriNetX USA network analysis
Real-world cardiovascular risk comparison of first-line osimertinib and earlier generation EGFR-TKIs in EGFR-mutated NSCLC: a TriNetX USA network analysis
Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC
Facial Age Predicts Survival Better Than Chronological Age in NSCLC undergoing radiotherapy: JAMA
Facial Age Predicts Survival Better Than Chronological Age in NSCLC undergoing radiotherapy: JAMA
Dynamics of the immune repertoire in recurrent, locally advanced NSCLC not amenable for definitive therapy and in stage IV disease receiving first-line chemotherapy
Dynamics of the immune repertoire in recurrent, locally advanced NSCLC not amenable for definitive therapy and in stage IV disease receiving first-line chemotherapy